Cylex Revenue and Competitors

Patented Technology Measures Immune Cell Function Organ Transplant Centers Adopt ImmuKnow® Cylex™ Inc. is a global life science company that develops and manufactures research and in vitro diagnostic products to illuminate immunity. ImmuKnow – FDA-cleared and commercialized in 2002 – is the in vitro diagnostic utilized to detect cell-mediated immunity in an immunosuppressed population: Allowing clinical researchers to simply and reproducibly measure immune cell function. ISO Certifications, 2008 Cylex received certification to ISO 13485:2003 and ISO 9001:2000. ISO 13485:2003 includes compliance with the Canadian Medical Devices Conformity Assessment System (CMDCAS). * Signifies compliance with internationally recognized standards in design, development and manufacturing of medical products * Issued by TÜV Rheinland of North America Method Patent Issued, 1998 An SBIR contract with the Department of Defense involved developing methods for monitoring immune response to a vaccine for Q-fever. From this preliminary work, Cylex developed a method patent for the measurement of T-cell activation. The growing company portfolio has patents in the U.S. and Australia and pending patents in Europe, Canada and Japan. Management Team The Cylex management team has extensive experience in developing, manufacturing, marketing and distributing medical diagnostic products